Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Buy” from Brokerages

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $27.80.

A number of research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. BTIG Research boosted their price target on Theravance Biopharma from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, November 26th. B. Riley began coverage on Theravance Biopharma in a research note on Friday, September 12th. They set a “buy” rating and a $28.00 price target for the company. Oppenheimer assumed coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th.

Theravance Biopharma Trading Up 0.9%

Shares of NASDAQ:TBPH opened at $18.74 on Friday. Theravance Biopharma has a 1 year low of $7.90 and a 1 year high of $20.33. The business has a fifty day simple moving average of $17.09 and a 200 day simple moving average of $14.10. The firm has a market cap of $949.30 million, a price-to-earnings ratio of 32.87 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.10. The business had revenue of $19.99 million during the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. On average, sell-side analysts forecast that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors have recently made changes to their positions in TBPH. Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma in the 3rd quarter valued at $10,611,000. Assenagon Asset Management S.A. raised its position in shares of Theravance Biopharma by 1,629.4% during the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares during the last quarter. Nuveen LLC acquired a new position in shares of Theravance Biopharma during the first quarter valued at about $3,348,000. Hillsdale Investment Management Inc. bought a new stake in shares of Theravance Biopharma in the third quarter valued at about $4,536,000. Finally, Jefferies Financial Group Inc. grew its position in Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock worth $3,054,000 after buying an additional 255,455 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.